EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms

Talha Badar iD, Yazan F Madanat iD, Amer M Zeidan iD

Future Oncology · 2023

DOI: 10.2217/fon-2023-0454 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Future Oncology, 2023. Verfasst von Talha Badar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology & Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL 32224, USA. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes. Die Arbeit nennt 74 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The majority of lower-risk myelodysplastic syndromes/neoplasms patients present with anemia. Historically, these patients were treated with erythropoiesis-stimulating agents (ESA), with modest responses. A subset of these patients with del(5q) may do better with lenalidomide. Recently, in randomized trials, luspatercept has shown better responses compared with ESAs in treatment-naive patients and imetelstat in patients refractory to ESAs. Other evaluated novel compounds (fostamatinib, H3B-880, roxadustat, pyruvate kinase receptor activator) have not yet shown meaningful efficacy. More needs to be done to improve outcomes; in pursuance of this, participation in clinical trials evaluating novel therapies should be encouraged. While lower-risk myelodysplastic syndromes/neoplasms tend to have an indolent course, a subset of them has a dismal prognosis. Improving prognostication and serial monitoring will help in identifying high-risk patients for appropriate management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesHumansRisk AssessmentPrognosisHematinicsAnemiaDisease ManagementLenalidomideTreatment OutcomeRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

AMLMDSprognosisrisk stratificationsomatic mutationstargeted drugs

Substanzen

HematinicsLenalidomide

Autor:innen und Institutionen

  • Division of Hematology & Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL 32224, USA.
  • Division of Hematology & Medical Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USA.
  • Leukemia Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA.
  • Section of Hematology, Department of Internal Medicine, Yale School of Medicine & Yale Cancer Center, New Haven, CT 06510, USA.

ORCID-Profile: Talha Badar, Yazan F Madanat, Amer M Zeidan

Zitieren

APA

Badar, T., Madanat, Y. F., & Zeidan, A. M. (2023). Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms. Future Oncology. https://doi.org/10.2217/fon-2023-0454

Vancouver

Badar T, Madanat YF, Zeidan AM. Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms. Future Oncology. 2023. doi:10.2217/fon-2023-0454

BibTeX
@article{Badar2023,
  author = {Badar, Talha and Madanat, Yazan F and Zeidan, Amer M},
  title = {Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms},
  journal = {Future Oncology},
  year = {2023},
  doi = {10.2217/fon-2023-0454}
}
Kostenlos starten →